News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Two-Year Clinical Study Supports Safety and Efficacy of Covidien plc (COV) Solitaire™ FR Revascularization Device


2/8/2013 9:45:14 AM

MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the Solitaireā„¢ FR Thrombectomy for Acute Revascularization (STAR) study. The two-year study evaluated the safety and efficacy of the Solitaire FR revascularization device in the treatment of acute ischemic stroke. Acute ischemic stroke (AIS) is the most prevalent form of stroke, representing up to 87% of all stroke-related cases worldwide.1 In AIS, the patient suffers from an acute blockage of blood flow (ischemia) to the brain, which, if not treated in a timely manner, leads to permanent neurological damage and possibly death. In 2008, the direct and indirect cost of stroke in U.S. was $39 billion.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES